Skip to main content
. 2020 Jan 30;9(1):1708064. doi: 10.1080/2162402X.2019.1708064

Figure 3.

Figure 3.

Administration of Tim-3 mAb PD-1 mAb synergistically inhibited tumor progression.

(a). Mean tumor volumes of MC38 tumor-bearing mice treated with indicated mAbs (n = 4 ~ 5). (b). Overall survival of ID8 tumor-bearing mice treated with indicated mAbs (n = 5). (c). Metastatic nodules in lung in 4T1 tumor-bearing mice treated with indicated mAbs (n = 4 ~ 5). *P < .05, one-way ANOVA test, Log-rank test, and student t test were performed.